Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: Long-term outcomes from a phase 1 study

February 9, 2018

Atezolizumab (MPDL3280A) monotherapy for patients with metastatic urothelial cancer: Long-term outcomes from a phase 1 study

Published on 02/08/2018

previous post: Efficacy of treatments for opioid-induced constipation: A systematic review and meta-analysis
next post: High density of M2-macrophages in acral lentiginous melanoma compared to superficial spreading melanoma